Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by INKOVAARA, J.
Right arrow Articles by TOKOLA, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by INKOVAARA, J.
Right arrow Articles by TOKOLA, O.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1983 Oxford University Press

research-article

CALCIUM, VITAMIN D AND ANABOLIC STEROID IN TREATMENT OF AGED BONES: DOUBLE-BLIND PLACEBO-CONTROLLED LONG-TERM CLINICAL TRIAL

JUKKA INKOVAARA, Associate Teacher of Medicine, GUIDO GOTHONI, Medical Director, RAIJA HALTTULA, Registered Nurse in Koukkuniemi Municipal Home, RAUNO HEIKINHEIMO, Chief Physician of Geriatric and OLAVI TOKOLA, Assistant Medical Director

Department of Clinical Sciences, University of Tampere Teiskontie 36, SF-33520 Tampere 52, Finland
Research Laboratories of Medica Pharmaceutical Company Ltd POB 325, SF-00101 Helsinki 10, Finland
Department Tampere City Hospital Parantolankatu 6, SF-33500 Tampere 50, Finland
Research Laboratories of Medica Pharmaceutical Company Ltd

In a double-blind trial, 327 patients (57 men) over 65 (mean age 79.5) years received all possible combinations of calcium carbonate 3 g, vitamin D3 1000 iu, methandienone 2.5 mg and/or placebos daily for 9 months. The higher incidence of bone fractures in the placebo group was not significant. Serum calcium, phosphorus, creatinine, aspartate aminotransferase and alkaline phosphatase were followed: the greatest changes occurred with methandienone, which thus reduced osteoporotic activity and increased the muscular mass most effectively; calcium carbonate had the poorest effect. Surprisingly, coronary mortality was higher among those taking all three active substances. With two treatments the increase was not significant, but when both the groups receiving a combination of any two of the treatments were compared with those taking only one or neither of these two treatments, a significant increase in coronary deaths was seen, most significant (P< 0.001) in those receiving vitamin D3 and methandienone.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Age AgeingHome page
T. J. Allain
Vitamin D and fracture prevention--treatment still indicated but clarification needed
Age Ageing, November 1, 2005; 34(6): 542 - 544.
[Full Text] [PDF]

Home page
 Endocr. Rev.Home page
E. Papadimitropoulos, G. Wells, B. Shea, W. Gillespie, B. Weaver, N. Zytaruk, A. Cranney, J. Adachi, P. Tugwell, R. Josse, et al.
VIII: Meta-Analysis of the Efficacy of Vitamin D Treatment in Preventing Osteoporosis in Postmenopausal Women
Endocr. Rev., August 1, 2002; 23(4): 560 - 569.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.